CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
Status:
WITHDRAWN
Trial end date:
2028-01-30
Target enrollment:
Participant gender:
Summary
This is a Phase I/II, multicenter, open-label, non-randomized study with four groups to characterize the pharmacokinetics and safety of Cabotegravir (CAB) and Rilpivirine (RPV) long-acting injectable (LA) during pregnancy and postpartum among people with HIV-1 viral suppression and their infants.
Phase:
PHASE1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)